J&J's Invokana Slows CKD Progression In Diabetes
Executive Summary
Positive top-line efficacy data from the CREDENCE study suggest the SGLT2 inhibitor slows the progress of chronic kidney disease in type 2 diabetics, a finding which may eventually have a positive effect on the sales performance of the diabetic therapy.
You may also be interested in...
Keeping Track: US FDA, Industry Roar Into Fourth Quarter With Bevy Of Regulatory Announcements
The latest drug development news and highlights from our US FDA Performance Tracker.
Keeping Track: Approvals For Mayzent, Mavenclad, Duaklir, Jatenzo And Cimzia
The latest drug development news and highlights from our US FDA Performance Tracker.
As J&J Sees Continued Drug Price Declines, CEO Urges Slow Policy Change Via Trump's Blueprint
J&J told investors to anticipate negative net drug pricing of 4%-6% across its portfolio in 2018, following a 4.6% negative impact in 2017. CEO Alex Gorsky also cautioned against changing drug pricing policy too quickly.